Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005039 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00005039 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 86 participants.
The verdict
NCT00005039, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL recombinant fowlpox-prostate specific antigen vaccine
- BIOLOGICAL recombinant vaccinia prostate-specific antigen vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2000-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005039
The ClinicalTrials.gov registry entry for NCT00005039 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00005039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005039 about?
NCT00005039 is a clinical study titled "Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)". Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells
What is the current status of trial NCT00005039?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2000-01.
What interventions are being tested in trial NCT00005039?
The interventions under investigation include: laboratory biomarker analysis (OTHER), recombinant fowlpox-prostate specific antigen vaccine (BIOLOGICAL), recombinant vaccinia prostate-specific antigen vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005039?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.